No Data
Warner Pharmaceutical (688799.SH): The heavy tartrate methoxamine injection has obtained the Pharmaceutical registration certificate.
On April 15, Gelonghui reported that Warner Pharmaceutical (688799.SH) announced that it received the Drug Registration Certificate for Heavy Tartrate Hydroxylamine Injection approved and issued by the National Medical Products Administration. Heavy Tartrate Hydroxylamine Injection is indicated for the prevention and treatment of acute hypotension occurring during intrathecal blockade anesthesia; for hypotension caused by bleeding, drug allergies, surgical complications, and shock combined with brain injury or brain tumors, it can be used for symptomatic treatment; it can also be used for hypotension caused by cardiogenic shock or sepsis. The company's Heavy Tartrate Hydroxylamine Injection has obtained the Drug Registration Certificate as a Class 3 Chemical Drug according to the new registration classification.
Warner Pharmaceuticals (688799.SH): The subsidiary has passed the Pharmaceutical GMP compliance inspection.
On April 14, Ge Long Hui reported that Warner Pharma (688799.SH) announced that its wholly-owned subsidiary, Hunan Warner Big Pharma Co., Ltd. (referred to as "Chiral Drug Company"), received a "Pharmaceutical GMP Compliance Inspection Notification" issued by the Hunan Provincial Drug Administration. The Active Pharmaceutical Ingredient, dexmedetomidine, located in Wangcheng District, Changsha, has passed the quality standard compliance inspection for pharmaceutical production (i.e., Pharmaceutical GMP compliance inspection).
There Is A Reason Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Price Is Undemanding
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Warner Pharmaceuticals (688799.SH): Xu Xiaoqiang has cumulatively reduced his shareholding by 1.0578%.
On March 25, Gelonghui reported that Warner Pharmaceuticals (688799.SH) announced it had received a notice from shareholders holding more than 5% of shares, Director Mr. Xu Yan and his concerted persons, Mr. Xu Xiaoqiang and Ms. Xu Yuehan, regarding the completion of the shareholding reduction plan. As of March 24, 2025, Mr. Xu Xiaoqiang had cumulatively reduced his holdings in the company by 992,200 shares, accounting for 1.0578% of the total share capital of the company; Ms. Xu Yuehan had cumulatively reduced her holdings by 352,000 shares, accounting for 0.3753% of the total share capital of the company. This shareholding reduction plan has been completed.
Hunan Warrant Pharmaceutical Withdraws Drug Registration Application
Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Shares Bounce 43% But Its Business Still Trails The Market
